Verenium Corp.
Formerly DIVERSA CORP, Industrial Genome Sciences, Inc., Industrial Biocatalysis, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2012 | $7 M | No. 2 | $2 to $10 million | options | SEC | |
| Sep 2009 | $14 M | No. 1 | $10 to $50 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Verenium Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2012).
SEC Form D · Dec 2012
It delivers 1 product named in the sources below.
See Products and services
The industry group it chose in its notices: Other Energy.
SEC Form D · Dec 2012
Products#
1 named by the sources below.
- enzyme
Wikidata · Wikidata: product or material produced (P1056)
Services#
No services of Verenium Corp. are on record.
Investors#
No investor of Verenium Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 8 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alexander A Fitzpatrick | Executive officer | Dec 2012 |
| James Levine | Executive officer | Dec 2012 |
| Janet Roemer | Executive officer | Dec 2012 |
| Jeffrey A Black | Executive officer | Dec 2012 |
| Carlos A. Riva | Executive officer | Oct 2009 |
| Gerald M. Haines | Executive officer | Oct 2009 |
| Gregory B. Powers | Executive officer | Oct 2009 |
| James B. Levine | Executive officer | Oct 2009 |
| Janet B. Roemer | Executive officer | Oct 2009 |
| Jeffrey G. Black | Executive officer | Oct 2009 |
| John B. Howe | Executive officer | Oct 2009 |
| Nell B. Jones | Executive officer | Oct 2009 |
| William H. Baum | Executive officer | Oct 2009 |
| Gregory Powers | Executive officer | Sep 2009 |
| Nell Jones | Executive officer | Sep 2009 |
| Cheryl F. Wenzinger | Director | Dec 2012 |
| Fernand F. Kaufman | Director | Dec 2012 |
| James H. Cavanaugh | Director | Dec 2012 |
| James Levine | Director | Dec 2012 |
| John F. Dee | Director | Dec 2012 |
| Joshua F. Ruch | Director | Dec 2012 |
| Michael F. Zak | Director | Dec 2012 |
| Peter F. Johnson | Director | Dec 2012 |
| Carlos A. Riva | Director | Oct 2009 |
| Simon F. Rich | Director | Oct 2009 |
| Cheryl Wenzinger | Director | Sep 2009 |
| Fernand Kaufmann | Director | Sep 2009 |
| Joshua Ruch | Director | Sep 2009 |
| Michael Zak | Director | Sep 2009 |
| Peter Johnson | Director | Sep 2009 |
| Simon Rich | Director | Sep 2009 |
About
American industrial biotechnology company.